| Patient | George H. W. Bush |
|---|---|
| Date of birth | 1959-06-12 |
| Identifiers | MRN HR-ML018-SYN; SSN (made up) 000-18-7245 |
| Document date | 2026-05-20 |
| Author | Douglas Whitford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review on methimazole for Graves' disease and atrial fibrillation. [S]
Mr. Bush returns twelve days after starting methimazole 20 mg daily, on metoprolol succinate 50 mg daily and apixaban 5 mg twice daily since his hospital stay. He has had no palpitations or irregular pulse on his home monitor and feels well. He has walked daily but has not run yet, as advised. He has had no fever, sore throat, mouth ulcers, rash, itching, yellow eyes, or dark urine on methimazole, and no bleeding or bruising on apixaban. He takes every dose. He has no eye pain, grittiness, or double vision. He saw the endocrinologist this morning, and radioactive iodine is planned for next week. [S]
| Element | Detail |
|---|---|
| Rhythm | No palpitations; regular pulse on home checks |
| Thyrotoxic symptoms | Feels well; still a little heat-intolerant |
| Methimazole safety | No fever, sore throat, rash, jaundice, or dark urine |
| Apixaban safety | No bleeding or bruising; no missed doses |
| Activity | Daily walks; not yet running |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No palpitations, chest pain, lightheadedness, or ankle swelling |
| Constitutional | Positive | Still a little heat-intolerant; no fever |
| Eyes | Negative | No grittiness, pain, redness, or double vision |
| Hematologic | Negative | No bleeding or bruising |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet each morning | Oral route | 2026-05-05 to 2026-07-17 | stopped | S |
| Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) | One tablet twice daily | Oral route | 2026-05-05 to 2026-09-11 | stopped | S |
| Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily | Two tablets once daily; stop three days before radioactive iodine | Oral route | 2026-05-08 to 2026-05-26 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-20 | Body height | 188 | cm | S |
| 2026-05-20 | Body weight | 86.4 | kg | S |
| 2026-05-20 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-05-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-20 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-20 | Heart rate | 72 | /min | S |
| 2026-05-20 | Respiratory rate | 14 | /min | S |
| 2026-05-20 | Body temperature | 36.9 | Cel | S |
| 2026-05-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-20 | Thyrotropin [Units/volume] in Serum or Plasma | 0.01 | m[IU]/L | 0.4-4 mIU/L | Low | S |
| 2026-05-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 2.2 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 2026-05-20 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 176 | ng/dL | 80-200 ng/dL | Normal | S |
| 2026-05-20 | Neutrophils [#/volume] in Blood by Automated count | 3.5 | 10*3/uL | 1.5-7.5 10*3/uL | Normal | S |
| 2026-05-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
Vital signs recorded on 2026-05-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; calmer than at intake |
| Eyes | No lid retraction, lid lag, proptosis, or redness; eye movements full |
| Neck | Diffusely enlarged, non-tender thyroid without nodules |
| Cardiovascular | Regular rhythm at 72 per minute; no murmur |
| Neurological | Fine tremor of the outstretched hands, less than at intake |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation | active | confirmed | I48.0 | S — Synthetic modern classification of a documented arrhythmia. |
| Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease | active | confirmed | E05.00 | S — Synthetic modern diagnosis confirmed by thyroid tests and TSH receptor antibody; the historical diagnosis is D. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Heart rate and rhythm | Every visit | Completed today | 72 per minute, regular; no recurrence of atrial fibrillation since discharge |
| Examination | Blood pressure | Every visit; target below 130/80 | Completed today | 132/70 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 86.4 kg, BMI 24.4 |
| Survey | Atrial fibrillation symptoms | Every visit | Completed today | None |
| Imaging | 12-lead ECG or rhythm strip | When rhythm assessment is indicated or symptoms change | Not indicated | Pulse regular on examination and on home checks; intake ECG in sinus rhythm |
| Imaging | Transthoracic echocardiogram | At diagnosis; repeat with clinical change | Up to date | Normal structure, left atrial size, and ejection fraction in hospital |
| Survey | CHA2DS2-VASc and HAS-BLED | Yearly and with any change in clinical status | Up to date | Scored at intake: CHA2DS2-VASc 1 (age 65 to 74), HAS-BLED 1 (age over 65) |
| Medication safety | Anticoagulant adherence and bleeding | Every visit | Completed today | No missed doses; no bleeding |
| Laboratory | Creatinine and eGFR on apixaban | At baseline and at least yearly | Up to date | Creatinine 0.92 mg/dL, eGFR 87 at intake; full dose is correct |
| Laboratory | Hemoglobin on anticoagulation | At least yearly; sooner with symptoms | Up to date | 14.8 g/dL at intake |
| Self-management | Alcohol, tobacco, and physical activity | Every visit | Completed today | No alcohol since the hospital stay; never used tobacco; daily walks, running to resume in steps |
| Survey | Sleep apnea symptom screen | At diagnosis and at least yearly | Deferred | Not asked at intake or today. Deviation: the screen due at diagnosis was missed; it is added to the next visit's checklist |
| Laboratory | Free T4 and total T3 on methimazole | Two to six weeks after starting, then every four to eight weeks | Completed today | Free T4 2.2 ng/dL, total T3 176 ng/dL, TSH 0.01 mIU/L |
| Laboratory | White cell count with differential and liver tests on methimazole | At baseline; then with fever, sore throat, jaundice, or other symptoms | Completed today | Checked before radioactive iodine at the consultant's request: neutrophils 3.5 x10³/µL, ALT 30 U/L |
| Medication safety | Methimazole side effects | Every visit while on methimazole | Completed today | None; written warning about fever and sore throat repeated |
| Examination | Eye assessment for Graves' orbitopathy | At diagnosis and before radioactive iodine | Completed today | No orbitopathy; never smoker, so no steroid cover is needed |
| Referral | Endocrinology consultation | At diagnosis of Graves' disease, to choose definitive treatment | Completed today | Seen today; radioactive iodine chosen |
Goal progress:
Guideline basis: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026)
Follow-up: Radioactive iodine next week. Review with thyroid tests in about seven weeks, or sooner for palpitations, fever, or sore throat. Next scheduled visit 2026-07-17: seven-week review after radioactive iodine. [S]